Together with the already available GIP receptor antagonists it may be possible to clarify further questions that have hitherto remained unanswered
In clinical trials, people lost up to 28.7% of their body weight after 68 weeks
Preliminary data published in June 2023 also suggests that GLP-1 drugs 'could modulate crucial pathways in the pathogenesis of inflammatory bowel disease (IBD), such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity' (Arvanitakis, Theocharis, Popovic
PKA induction from native GLP-1 phosphorylates a key serine residue in NOS [40]
Acylated GLP-1RAs, like liraglutide and semaglutide, heve limited direct BBB penetration but still reach critical areas such as the arcuate nucleus (ARH) through indirect pathways [125]
Demand for NHS weight loss injections creates practical workload for GP practices and PCNs